Research and Markets: Thromboembolism - Pipeline Review, H2 2011 - A snapshot of the global therapeutic scenario for Thromboembolism

DUBLIN--()--Research and Markets(http://www.researchandmarkets.com/research/ab76d6/thromboembolism) has announced the addition of Global Markets Direct's new report "Thromboembolism - Pipeline Review, H2 2011" to their offering.

Global Markets Direct's, 'Thromboembolism - Pipeline Review, H2 2011', provides an overview of the Thromboembolism therapeutic pipeline. This report provides information on the therapeutic development for Thromboembolism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thromboembolism. 'Thromboembolism - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Key Topics Covered:

  • Introduction
  • Global Markets Direct Report Coverage
  • Thromboembolism Overview
  • Therapeutics Development
  • An Overview of Pipeline Products for Thromboembolism
  • Thromboembolism Therapeutics under Development by Companies
  • Thromboembolism Therapeutics under Investigation by Universities/Institutes
  • Late Stage Products
  • Comparative Analysis
  • Mid Clinical Stage Products
  • Comparative Analysis
  • Early Clinical Stage Products
  • Comparative Analysis
  • Pre-Clinical Stage Products
  • Comparative Analysis
  • Thromboembolism Therapeutics - Products under Development by Companies
  • Thromboembolism Therapeutics - Products under Investigation by Universities/Institutes
  • Companies Involved in Thromboembolism Therapeutics Development
  • Thromboembolism - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Late Stage Drug Profiles
  • Thromboembolism Therapeutics - Drug Profile Updates
  • Thromboembolism Therapeutics - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Companies Mentioned:

  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Sanofi-Aventis
  • Eli Lilly and Company
  • Daiichi Sankyo Company, Ltd
  • Generex Biotechnology Corporation
  • BioLineRx, Ltd.
  • Novartis AG
  • Bayer AG
  • ARYx Therapeutics
  • Portola Pharmaceuticals, Inc.
  • Emisphere Technologies, Inc.
  • ThromboGenics NV
  • Merrion Pharmaceuticals Plc
  • Italfarmaco S.p.A.
  • Biolex Therapeutics, Inc.
  • Regado Biosciences.

For more information visit http://www.researchandmarkets.com/research/ab76d6/thromboembolism

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716